News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Intravesical pembrolizumab delivers antitumour activity in NMIBC
08 Sep 2022
byTristan Manalac
A recent first-in-human study has shown that directly applying pembrolizumab to the bladder is a safe and effective treatment option for patients with nonmuscle-invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment.
08 Sep 2022

Trabectedin fails to improve survival outcomes in recurrent ovarian, primary peritoneal, or fallopian tube cancer
07 Sep 2022
byRoshini Claire Anthony
Trabectedin did not improve overall survival (OS) or progression-free survival (PFS) compared with chemotherapy in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer and BRCA mutation or BRCAness phenotypes, according to results of the phase III MITO23 trial.
07 Sep 2022






